Quantitative assessment of myelination and remyelination is a primary endpoint for many AAV-based neurological gene therapy programs. Traditional histological methods often lack the precision and scalability required to detect subtle therapeutic effects on axonal integrity and myelin sheath thickness across entire CNS regions. This page details the application of high-resolution whole slide imaging (WSI) coupled with AI-driven image analysis to provide objective, reproducible quantification of myelination changes, supporting robust preclinical data packages for IND submissions.

What is the primary advantage of WSI over traditional microscopy for myelin analysis?

WSI digitizes entire tissue sections at high magnification, enabling automated, unbiased analysis of the entire anatomical region of interest. This eliminates the sampling bias inherent in manual microscopy and provides a comprehensive dataset for quantifying metrics like g-ratio, myelin basic protein (MBP) area, and oligodendrocyte cell counts.

Which stains are compatible with your quantitative myelination platform?

Our platform is optimized for classic myelin stains such as Luxol Fast Blue (LFB) and immunohistochemical (IHC) markers including MBP and proteolipid protein (PLP). We also develop custom multiplex IHC/IF protocols to co-localize myelin markers with axonal neurofilaments or glial cell markers (Olig2, GFAP, Iba1).

How does the platform ensure data integrity for GxP-compliant studies?

The entire workflow, from slide scanning to data analysis, operates within a GxP framework. Our systems, including our high-resolution slide scanners, are fully validated. The analysis software provides a complete audit trail, ensuring data is attributable, legible, contemporaneous, original, and accurate (ALCOA+).

What is the typical turnaround time for a standard myelination study?

While project-dependent, our automated workflow provides significant acceleration over manual methods. Following slide preparation, quantitative data is generated efficiently, providing rapid pathology insights accelerating preclinical readouts.

A Data-Driven Approach to Preclinical Validation

The value of a robust preclinical data package is well-established. Studies demonstrating long-term safety and durable clinical responses, sometimes mediated through secondary mechanisms, highlight the need for comprehensive initial characterization (PMID: 16243818). Similarly, successful efficacy demonstrations in relevant translational models are a prerequisite for clinical advancement (PMID: 22985273).

Our quantitative histology platform contributes directly to this goal. By providing objective, reproducible data on key structural endpoints, we strengthen the overall IND package. This commitment to data quality is reflected in the 100% IND-enabling study success rate for programs conducted under our GxP systems since 2019. (The Franklin Biolabs brand was launched in 2024).

Our process involves:

• Optimized Tissue Preparation: Standardized protocols for fixation, processing, and sectioning to preserve CNS tissue integrity.

• Automated Staining: Consistent application of LFB, IHC, or immunofluorescence stains for myelin and cellular markers.

• High-Resolution Scanning: Digitization of whole slides at 20x or 40x magnification.

• AI-Powered Analysis: Deployment of validated algorithms to identify and quantify myelinated axons, measure myelin thickness, and count relevant cell populations (e.g., oligodendrocytes, microglia).

• Integrated Reporting: Delivery of a comprehensive data package including representative images, quantitative data tables, and statistical analysis in a GxP-compliant format.

This structured approach ensures that the histological data generated is not only scientifically sound but also fully defensible for regulatory review.